Filtered By:
Drug: Activase
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 669 results found since Jan 2013.

Effect of mechanical thrombectomy with and without intravenous thrombolysis on the functional outcome of patients with different degrees of thrombus perviousness
ConclusionPatients with thrombi of lower perviousness were recommended to undergo intravenous alteplase followed by endovascular thrombectomy, and those with thrombi of higher perviousness could undergo thrombectomy alone.
Source: Neuroradiology - August 29, 2023 Category: Radiology Source Type: research

Comparing adverse Events of tenecteplase and alteplase: A Real-World analysis of the FDA adverse Event Reporting System (FAERS)
CONCLUSION: This study identified and compared signals of ADRs associated with tenecteplase and alteplase, although tenecteplase is as effective as alteplase and has advantages such as ease of use and affordability, it cannot replace alteplase in the treatment of AIS until its safety profile is fully recognized. Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of ...
Source: Expert Opinion on Drug Safety - August 9, 2023 Category: Drugs & Pharmacology Authors: Fang-E Shi Zhe Yu Chengyue Sun Peiliang Gao Haiyan Zhang Jihong Zhu Source Type: research

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
Source: Neurology and Therapy - August 8, 2023 Category: Neurology Source Type: research

Low-dose intravenous recombinant tissue plasminogen activator in acute ischemic stroke without large vessel occlusion screened by 3T MRI
CONCLUSIONS: Our study indicates the efficacy and safety of low-dose rTPA treatment for AIS without LVO within 4.5 hours. Patient selection for rTPA by 3T MRI decreased complications and mortality.PMID:37522667 | DOI:10.26355/eurrev_202307_33126
Source: European Review for Medical and Pharmacological Sciences - July 31, 2023 Category: Drugs & Pharmacology Authors: Q-S Huynh C-C Tran H-T Nguyen-Thi T-T Nguyen H-L Phan-Thi D-T Luu-Dang M-T Le M-D Nguyen Source Type: research